Development Pipeline

Our novel, biomarker-driven product pipeline addresses distinct molecular targets and biologic pathways, including targeted therapies and immunotherapies that are key drivers of cancer progression.

Development Pipeline

Our biomarker-driven product pipeline addresses distinct molecular targets and biologic pathways that are relevant across a variety of cancers.

Ikena is leveraging its core capabilities in oncology drug discovery, translational sciences, and clinical development to build a next generation pipeline of targeted oncology therapies and immunotherapies that addresses a broad range of cancers. By targeting defined subgroups of patients based on their biomarker profiles, we are methodically building a growing pipeline of unique patient-directed therapies: bringing the right drug to the right patient. We have two product candidates currently in the clinic: IK-007 is in Phase 1b/2 for the treatment of microsatellite stable colorectal cancer and PD-1/L1 refractory non-small cell lung cancer, and IK-175 is in Phase 1 for the treatment of solid tumors, including bladder cancer.
Program
Target
Indication
  • Disc.
  • Pre-Cli.
  • Ph1
  • Ph2

Targeted Oncology

TEAD Inhibitor TEAD Inhibitor
TEAD
Hippo-mutated cancers
TEAD
Hippo-mutated cancers
  • Pre-C
RAS Signaling RAS Signaling
Undisclosed
KRAS-mutated cancers
Undisclosed
KRAS-mutated cancers
  • Disc.
Discovery Discovery
Multiple
Undisclosed
Multiple
Undisclosed
  • Disc.

Immunotherapy

IK-007 + Pembrolizumab1 IK-007 + Pembrolizumab1
EP4
Biomarker-enriched MSS CRC and refractory NSCLC
EP4
Biomarker-enriched MSS CRC and refractory NSCLC
  • PH1
IK-1752 IK-1752
AHR
Biomarker-enriched bladder cancer
AHR
Biomarker-enriched bladder cancer
  • PH1
BMS Collaboration
IK-4122 IK-4122
Kynurenine
Undisclosed
Kynurenine
Undisclosed
  • Pre-C
BMS Collaboration

Explore the scientific research that supports our pipeline.